Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease
NCT00861601
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
38
Enrollment
INDUSTRY
Sponsor class
Conditions
Liver Diseases
Interventions
DRUG:
eltrombopag 12.5 milligrams (mg) tablet
DRUG:
eltrombopag 25 mg tablet
Sponsor
GlaxoSmithKline